Current Issues in Immunoglobulin Therapies
While immunoglobulin therapy has been available in healthcare for many years, the issues related to new brands, product availability, costs and safety continue to change. The shortages of the last ten years and concerns over the transmission of Hepatitis and/or HIV have been replaced with other equally complex and challenging concerns to both patients and clinicians. This article examines the most urgent of those concerns and describes the relevance these issues have to clinical practice.Abstract
Contributor Notes
Marilyn Hanchett, RN, PhD is Director of Clinical Affairs at IgG America and can be reached at mbanchett@iggamerica.com.
Mary Beth Friedel, RPh is Director of Pharmacy at IgG America. She can be contacted at mfriedel@iggamerica.com.
Christine Coursey, RN is Director of Nursing at IgG America and can be contacted at ccoursey@iggamerica. You can also contact any of the authors at 877-674-9700 Eastern Time.